Clinical operations field note
From Site Finding to Study Decision: Verifying Clinical Trial Issue Closure
Connect site findings to sponsor decisions with a documented action owner, cross-site review, and an effectiveness check using Lampgen’s SIGNAL framework.
By Lampgen Clinical Research
Updated

2 min read · estimated
Closing an action item and establishing that the underlying issue is controlled are different judgments. A useful monitoring record connects the finding to its significance, the responsible decision maker, the agreed response, and the next opportunity to assess recurrence.
FDA’s monitoring Q&A covers planning, communication, and responses to findings. ICH E6(R3) also addresses sponsor oversight and follow-up. Lampgen’s approach below applies those ideas to a worked operational question; the example is illustrative.
Start with an observation that can be checked
Consider a hypothetical missed protocol-defined specimen window. Establish what happened, which records support it, and whether the issue concerns the procedure, the documentation, or the review of an available result. Different causes can require different actions.
Before treating the event as an isolated site issue, check whether a comparable pattern exists elsewhere. Use the relevant activity as context: a site with more eligible visits has more opportunities for a window to be missed. Counts without that context can be misleading.
Use SIGNAL™ to organize the judgment
- Spot: state the observable finding and its evidence.
- Investigate: establish what contributed to the finding.
- Gauge: examine whether the pattern appears elsewhere in the agreed scope.
- Name: describe the risk and the decision that needs an owner.
- Act: assign the authorized response, responsible person, and timing.
- Learn: review the next relevant activity for recurrence and adjust if needed.
Schedule the effectiveness check when assigning the action
If the suspected cause is an unclear handoff, record how the handoff will change and who will implement it. Specify the next relevant collection window or review period when the team can assess whether the expected records are complete. Training attendance alone may not answer that question.
Use the study’s agreed escalation routes for urgent issues. A periodic trend review must not delay safety communication or another time-sensitive study decision. The sponsor determines the appropriate response and retains its oversight responsibility.
Separate the method, service, and supporting software
SIGNAL™ is Lampgen’s Spot, Investigate, Gauge, Name, Act, Learn framework. SIGNAL Managed Monitoring is the scoped ongoing service, with a designated oversight lead, selected report review, cross-site trend review, action tracking, and a sponsor dashboard.
The SIGNAL Oversight Workspace supports the service. Its public prototype contains fictional data and is non-validated; it is for demonstration. A sample dashboard can show the reporting structure, while the actual review cadence, access, scope, and responsibilities are agreed for an engagement. No example establishes a performance guarantee.